IVF OutcomesNCT07110285
Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm.
A study testing Artificial intelligence-based algorithm in people with IVF Outcomes, run by FertilAI at 1 site in Israel.
Trial summary
To compare the number of mature oocytes following a GnRH antagonist in-vitro fertilization stimulation cycle when comparing trigger day timing decision by physicians versus an artificial intelligence-based algorithm Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- IVF Outcomes
- What is being tested?
- Artificial intelligence-based algorithm
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteIsrael
- Study dates
- 21 May 2025to 21 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- All patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed).
Who cannot join
- Loss to follow-up, patient retracts consent to participate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Israel1 site, 1 recruiting
- Recruiting
Herzliya Medical Center
Herzliya, 74077
Michal Youngster, 0506430111, michalyo@gmail.com
Michal Youngster, MD
About this study
Official title: Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm - A Randomized Control Study.
To compare the number of mature oocytes following a GnRH antagonist in-vitro fertilization stimulation cycle when comparing trigger day timing decision by physicians versus an artificial intelligence-based algorithm
Read the detailed description
Examination of all patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed). The number of mature oocytes will be compared between cycles where trigger day timing was decided by the treating physician versus an artificial intelligence-based algorithm.
- Conditions
- IVF Outcomes
- Being tested
- Artificial intelligence-based algorithm
- Keywords
- Trigger day decision, In-vitro fertilization, Mature oocytes, Artifical intelligence-based algorithm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Artificial intelligence-based algorithmOther
Trigger day timing decision by an artificial intelligence-based algorithm
| Study group | Role | What they receive |
|---|---|---|
| Physician-based trigger day timing decision | No intervention | Trigger day timing is decided on by the treating physician |
| Artificial intelligence-based algorithm trigger day timing decision | Experimental | Trigger day timing decision by an artificial intelligence-based algorithm Receives: Other: Artificial intelligence-based algorithm |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mature oocyte yield
The number of mature oocytes collected during a single egg retrieval cycle
Measured: 2 years
Secondary outcomes (1)
Oocyte yield
Number of retrieved oocytes during an egg collection cycle
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Aug 2025
- Study start21 May 2025
- Primary completionMay 2027 (estimated)
- Study completion21 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IVF OutcomesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- FertilAI
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Principal investigator, Michal Youngster, FertilAI
- Investigators
- Ariel Hourvitz, MD, Principal investigator, Herzeliya Medical Center, Israel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07110285
- Sponsor's protocol ID
- 0015-23-HMC
- Status last verified
- May 2025
- First submitted
- 31 Jul 2025
- Last updated
- 12 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data regarding patient demographics, characteristics and cycle outcomes (anynomized)
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm - A Randomized Control Study.
- ClinicalTrials.gov ID
- NCT07110285
- Acronym / sponsor ID
- 0015-23-HMC
- Conditions
- IVF Outcomes
- Keywords
- Trigger day decision, In-vitro fertilization, Mature oocytes, Artifical intelligence-based algorithm
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- FertilAIIndustry (pharma, biotech, devices)
- Study start
- 21 May 2025 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- 21 May 2028 (estimated)
- First posted
- 7 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the number of mature oocytes following a GnRH antagonist in-vitro fertilization stimulation cycle when comparing trigger day timing decision by physicians versus an artificial intelligence-based algorithm
Detailed description
Examination of all patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed). The number of mature oocytes will be compared between cycles where trigger day timing was decided by the treating physician versus an artificial intelligence-based algorithm.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Physician-based trigger day timing decision | No intervention | –Trigger day timing is decided on by the treating physician |
| Artificial intelligence-based algorithm trigger day timing decision | Experimental | Other: Artificial intelligence-based algorithmTrigger day timing decision by an artificial intelligence-based algorithm |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- All patients undergoing an ovarian stimulation cycle utilizing the GnRH antagonist protocol for oocyte cryopreservation or for fertilization via intracytoplasmic sperm injection (ICSI) (any treatment where oocytes are denuded and maturity may be assessed).
Key exclusion criteria (1 listed)
- Loss to follow-up, patient retracts consent to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Artificial intelligence-based algorithmTrigger day timing decision by an artificial intelligence-based algorithm | Other | Artificial intelligence-based algorithm trigger day timing decision |
Primary outcome
Mature oocyte yield
Time frame: 2 years
The number of mature oocytes collected during a single egg retrieval cycle
1 secondary outcome
Oocyte yield
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2026.
- Individual participant dataSharing planned: Yes. Data regarding patient demographics, characteristics and cycle outcomes (anynomized)
Related trials for IVF Outcomes
RecruitingObservational study
Machine-Learning Prediction of Pregnancy Outcomes After Assisted Reproductive Treatments
IVF Outcomes, Prediction Models
Not yet recruitingObservational study
Effect of Body Mass Index on ICSI Outcomes
Infertility, Obesity
Active, not recruitingObservational study
Sperm Selection Strategies and Male-Factor Phenotypes in ICSI
Assisted Reproductive Technology, Assisted Reproductive Technology Outcomes
Recruiting
Effectiveness of Live Motile Sperm Sorting Device on IVF Outcomes in Advanced Paternal Age
Male Infertility, Advanced Paternal Age
Enrolling by invitationObservational study
BMI Versus Body Fat Percentage - Which is the Better Predictor of Fertility Outcomes in IVF Cycles?
Infertility (IVF Patients), BMI
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ariel Hourvitz, MD principal investigator
Herzeliya Medical Center, Israel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Artificial intelligence-based algorithm in people with IVF Outcomes, run by FertilAI at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michal Youngster, MD (+972-50-643-0111, michalyo@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mature oocyte yield (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2026.